| | | SCIENCE NEWS |
Navidea Reports Clinical Data Demonstrating Manocept™ Agent Localizes in Multiple KS Lesions
Navidea Biopharmaceuticals, Inc. and its subsidiary, Macrophage Therapeutics, Inc. announced that imaging results from the Manocept™ clinical trial in Kaposi’s Sarcoma (KS) and other preclinical studies were presented. [Press release from Navidea Biopharmaceuticals, Inc. discussing research presented at the at the 18th International Workshop on Kaposi’s Sarcoma Herpesvirus (KSHV) and Related Agents, Hollywood]
Press Release
Alnylam Reports New Positive Clinical Data for ALN-AT3, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders
Alnylam Pharmaceuticals, Inc. announced that new positive data from its ongoing Phase I clinical trial with ALN-AT3 – an investigational RNAi therapeutic for the treatment of hemophilia and rare bleeding disorders. [Press release from Alnylam Pharmaceuticals, Inc. discussing research presented at the at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress, Toronto] Press Release
From our sponsor: 3D intestinal organoid culture is made easy with IntestiCult™. Request a sample.
|
| | | POLICY |
US Vaccine Researcher Sentenced to Prison for Fraud
Dong-Pyou Han, a former biomedical scientist at Iowa State University in Ames, was sentenced to 57 months for fabricating and falsifying data in HIV vaccine trials. Han has also been fined $7.2 million and will be subject to three years of supervised release after he leaves prison. [Nature News] Editorial
Greek Scientists Lose Access to Digital Journals
The Internet portal that provides scientists in many Greek universities and research institutes with access to electronic journals from 27 publishers suspended many of its services because the government has not provided the funds to keep it going. [Nature News] Editorial
|
| | | BUSINESS |
AMAG Pharmaceuticals to Acquire Cord Blood Registry
AMAG Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to acquire Cord Blood Registry®, the world’s largest stem cell collection and storage company serving pregnant women and their families, for $700 million. [Cord Blood Registry®] Press Release
Amarna Therapeutics Teaming Up with Austrian CBmed in the Development of Immunotherapies
Amarna Therapeutics announced that it has entered into a cooperation with Austrian Center for Biomarker Research in Medicine (CBmed), for the development of immunotherapies against acute lymphoblastic leukemia, obesity, diabetes mellitus type 2 and atherosclerotic cardiovascular disease. [Amarna Therapeutics] Press Release
Biogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology
Biogen and AGTC announced a broad collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases. The collaboration will focus on the development of a portfolio of AGTC’s therapeutic programs, including both a clinical stage candidate and a pre-clinical candidate for orphan diseases of the retina that can lead to blindness in children and adults. [Biogen]
Press Release
STEMCELL Technologies Launches Innovative Products to Support CAR T Cell Research
STEMCELL Technologies Inc. announced the launch of ImmunoCult™ Human T Cell Activator reagents and ImmunoCult™-XF T Cell Expansion Medium to support T cell researchers in their goal to develop CAR T cell immunotherapeutics. The products provide significant benefits compared to existing technologies. [STEMCELL Technologies Inc.]
Press Release
CTCA at Western Launches 3rd New Clinical Trial Combining Immunotherapy with Chemotherapy
Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma. [Cancer Treatment Centers of America® (EurekAlert!)] Press Release
TxCell Announces FDA Acceptance of IND for Ovasave
TxCell SA announced that the United States Food and Drug Administration (FDA) has accepted TxCell’s Investigational New Drug (IND) application for the company’s lead product, Ovasave®, currently in a Phase IIb clinical trial for the treatment of patients with refractory Crohn’s disease. [TxCell SA] Press Release
Exelixis Provides Update on Genentech’s Pending New Drug Application for Cobimetinib, an Exelixis-Discovered Compound
Exelixis’ partner Genentech informed Exelixis that, in order to accommodate its review of a supplemental data submission, the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act action date for its review of Genentech’s New Drug Application for cobimetinib by the standard extension period of three months. [Exelixis, Inc.] Press Release
R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labor and Welfare
R-Japan Co., Ltd. obtained the license of cell processing facility under the Act on the Safety of Regenerative Medicine from the Ministry of Health, Labor and Welfare Kinki Bureau of Health and Welfare. [R-Japan Co., Ltd. (PR Newswire Association LLC)] Press Release
|
|
